These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25644944)

  • 1. Curcumin as a putative antidepressant.
    Seo HJ; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2015 Mar; 15(3):269-80. PubMed ID: 25644944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.
    Lopresti AL; Hood SD; Drummond PD
    J Psychopharmacol; 2012 Dec; 26(12):1512-24. PubMed ID: 23035031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin in antidepressant treatments: An overview of potential mechanisms, pre-clinical/clinical trials and ongoing challenges.
    Zhang Y; Li L; Zhang J
    Basic Clin Pharmacol Toxicol; 2020 Oct; 127(4):243-253. PubMed ID: 32544307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
    Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
    J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.
    Bschor T; Lewitzka U; Sasse J; Adli M; Köberle U; Bauer M
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S230-4. PubMed ID: 14677084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.
    Barden N
    J Psychiatry Neurosci; 2004 May; 29(3):185-93. PubMed ID: 15173895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function.
    Budziszewska B
    Pol J Pharmacol; 2002; 54(4):343-9. PubMed ID: 12523487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function.
    Nikisch G
    Neuro Endocrinol Lett; 2009 Mar; 30(1):11-6. PubMed ID: 19300389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of new antidepressants: can formal models help? A first attempt using a model of the hippocampal control over the HPA-axis based on a review from the literature.
    Belzung C; Billette de Villemeur E
    Behav Pharmacol; 2010 Dec; 21(8):677-89. PubMed ID: 21051994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of endocrine hormones for treating depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Dec; 48(12):13-6. PubMed ID: 21117521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways.
    Taylor C; Fricker AD; Devi LA; Gomes I
    Cell Signal; 2005 May; 17(5):549-57. PubMed ID: 15683730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
    Lopresti AL; Maes M; Maker GL; Hood SD; Drummond PD
    J Affect Disord; 2014; 167():368-75. PubMed ID: 25046624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saponins: the phytochemical with an emerging potential for curing clinical depression.
    Abbas G; Rauf K; Mahmood W
    Nat Prod Res; 2015; 29(4):302-7. PubMed ID: 25075957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in development for the treatment of depression.
    Grady MM; Stahl SM
    CNS Spectr; 2013 Dec; 18 Suppl 1():37-40; quiz 41. PubMed ID: 24252548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.
    Bergman J; Miodownik C; Bersudsky Y; Sokolik S; Lerner PP; Kreinin A; Polakiewicz J; Lerner V
    Clin Neuropharmacol; 2013; 36(3):73-7. PubMed ID: 23673908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of the hypothalamo-hypophyseal-adrenocortical system in the specific activity of antidepressive agents].
    Arushanian EB; El'bek'ian KS
    Eksp Klin Farmakol; 1995; 58(3):65-70. PubMed ID: 7663305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurogenesis and antidepressant action.
    Park SC
    Cell Tissue Res; 2019 Jul; 377(1):95-106. PubMed ID: 31165247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antidepressant-like activity of novel water-soluble curcumin formulations and St. John's wort in behavioral paradigms of despair.
    Kulkarni SK; Akula KK; Deshpande J
    Pharmacology; 2012; 89(1-2):83-90. PubMed ID: 22343362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentials of curcumin as an antidepressant.
    Kulkarni S; Dhir A; Akula KK
    ScientificWorldJournal; 2009 Nov; 9():1233-41. PubMed ID: 19882093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.
    Kopschina Feltes P; Doorduin J; Klein HC; Juárez-Orozco LE; Dierckx RA; Moriguchi-Jeckel CM; de Vries EF
    J Psychopharmacol; 2017 Sep; 31(9):1149-1165. PubMed ID: 28653857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.